Medeor Therapeutics Stock (MEOT)

Medeor Therapeutics is a biotechnology company that dedicates to the discovery, development and commercialization of transformative and personalized cellular immunotherapies. Its growing team of professionals possesses remarkably deep expertise in cellular immunotherapy and transplantation product development. Its pipeline addresses critical medical needs of the approximately 120,000 annual organ transplant recipients worldwide, including greater than 30,000 annual organ transplant recipients in the US alone. Medeor's product candidates are intended to minimize or eliminate chronic anti-rejection, immunosuppressive drug regimens used by new recipients of living donor transplants as well as those who have received a living donor transplant in the past (i.e., 2nd Chance Therapy). The company holds exclusive worldwide licenses to a series of breakthrough technologies, all discovered at Stanford University. Medeor is headquartered in San Mateo, California.